» Articles » PMID: 20506312

Genetic Etiology of Parkinson Disease Associated with Mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 Genes: a Mutation Update

Overview
Journal Hum Mutat
Specialty Genetics
Date 2010 May 28
PMID 20506312
Citations 226
Authors
Affiliations
Soon will be listed here.
Abstract

To date, molecular genetic analyses have identified over 500 distinct DNA variants in five disease genes associated with familial Parkinson disease; alpha-synuclein (SNCA), parkin (PARK2), PTEN-induced putative kinase 1 (PINK1), DJ-1 (PARK7), and Leucine-rich repeat kinase 2 (LRRK2). These genetic variants include approximately 82% simple mutations and approximately 18% copy number variations. Some mutation subtypes are likely underestimated because only few studies reported extensive mutation analyses of all five genes, by both exonic sequencing and dosage analyses. Here we present an update of all mutations published to date in the literature, systematically organized in a novel mutation database (http://www.molgen.ua.ac.be/PDmutDB). In addition, we address the biological relevance of putative pathogenic mutations. This review emphasizes the need for comprehensive genetic screening of Parkinson patients followed by an insightful study of the functional relevance of observed genetic variants. Moreover, while capturing existing data from the literature it became apparent that several of the five Parkinson genes were also contributing to the genetic etiology of other Lewy Body Diseases and Parkinson-plus syndromes, indicating that mutation screening is recommendable in these patient groups.

Citing Articles

Exploring the Potential of tsRNA as Biomarkers for Diagnosis and Treatment of Neurogenetic Disorders.

Zhao S, Wang Y, Zhou L, Li Z, Weng Q Mol Neurobiol. 2025; .

PMID: 40009263 DOI: 10.1007/s12035-025-04760-5.


Evolving Landscape of Parkinson's Disease Research: Challenges and Perspectives.

Tenchov R, Sasso J, Zhou Q ACS Omega. 2025; 10(2):1864-1892.

PMID: 39866628 PMC: 11755173. DOI: 10.1021/acsomega.4c09114.


Biological Function Analysis of MicroRNAs and Proteins in the Cerebrospinal Fluid of Patients with Parkinson's Disease.

Hwang J, Kim S, George N, Kwon M, Jang Y, Lee S Int J Mol Sci. 2025; 25(24.

PMID: 39769025 PMC: 11678473. DOI: 10.3390/ijms252413260.


A Structural Proteomics Exploration of Synphilin-1 and Alpha-Synuclein Interaction in Pathogenesis of Parkinson's Disease.

Tripathi A, Mondal R, Mandal M, Lahiri T, Pal M Biomolecules. 2025; 14(12.

PMID: 39766295 PMC: 11674031. DOI: 10.3390/biom14121588.


Parkinson's Disease Pathogenic Variants: Cross-Ancestry Analysis and Microarray Data Validation.

Hong S, Koretsky M, Lichtenberg J, Leonard H, Pitz V medRxiv. 2025; .

PMID: 39763553 PMC: 11702716. DOI: 10.1101/2024.12.16.24319097.


References
1.
Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

2.
Periquet M, Lucking C, Vaughan J, Bonifati V, Durr A, De Michele G . Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects. Am J Hum Genet. 2001; 68(3):617-26. PMC: 1274475. DOI: 10.1086/318791. View

3.
Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E . The ubiquitin pathway in Parkinson's disease. Nature. 1998; 395(6701):451-2. DOI: 10.1038/26652. View

4.
Belin A, Westerlund M, Sydow O, Lundstromer K, Hakansson A, Nissbrandt H . Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Mov Disord. 2006; 21(10):1731-4. DOI: 10.1002/mds.21016. View

5.
Goldwurm S, Di Fonzo A, Simons E, Rohe C, Zini M, Canesi M . The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet. 2005; 42(11):e65. PMC: 1735940. DOI: 10.1136/jmg.2005.035568. View